Multiple MyelomaNCT07927023
A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
An observational study of Multiple Myeloma, run by Pfizer.
Trial summary
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma
- What is being tested?
- Elranatamab
- How many people
- 1 participants
- Where
- No sites listed yet
- Study dates
- 9 Nov 2026to 1 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients treated with elranatamab will come from the MagnetisMM-5 trial. Patients treated with the standard-of-care therapies will come from electronic health record databases in Germany.
Who may be able to join
- Male or Female aged 18 years and older at index date
- Diagnosis of MM
- Measurable disease according to IMWG criteria
- Prior anti-MM therapy (1-3 prior lines of therapy)
- ECOG performance status ≤2
Who cannot join
- Acute plasma cell leukemia
- Amyloidosis
- Smoldering MM
- Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
- Ongoing Grade 2 or higher peripheral sensory or motor neuropathy.
- Active systemic infection or SARS-CoV-2 viral infection
Show all 14Show fewer
- Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ
- Other surgical, medical, or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Previous treatment with a BCMA-directed therapy or a CD3-redirecting therapy.
- Anti-CD38-directed therapy within 6 months preceding the first dose of treatment in this study
- Refractory to prior anti-CD38-directed therapy (disease progression while on or within 60 days of the last dose of any anti-CD38-directed therapy or failure to achieve at least MR).
- Previous pomalidomide therapy
- Administration with an investigational drug within 30 days prior to index
- For women of childbearing potential: Pregnancy test positive at screening
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparative Effectiveness of Elranatamab Monotherapy in the MagnetisMM-5 Clinical Trial Versus a Real-World External Control Arm of Patients With Relapsed/Refractory Multiple Myeloma With Prior Treatment of Lenalidomide and Proteasome Inhibitor From the Therapy Monitor Multiple Myeloma Dataset in Germany (BasecaMMp)
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, we will use data from the phase 3 clinical trial (MagnetisMM-5). We will also use data from a real-world database, representing the SOC in clinical practice. This study does not seek any participants for enrollment. We will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help us to know how well elranatamab can be used for RRMM treatment.
Read the detailed description
Comparative effectiveness of elranatamab monotherapy in the MagnetisMM-5 clinical trial versus a real-world external control arm of patients with relapsed/refractory multiple myeloma with prior treatment of lenalidomide and proteasome inhibitor from the Therapy Monitor Multiple Myeloma dataset in Germany (BasecaMMp)
- Conditions
- Multiple Myeloma
- Being tested
- Elranatamab, Standard of Care
- Keywords
- Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific, Elranatamab, MagnetisMM-5
- Medical subject headings
- Multiple Myeloma, Neoplasms, Plasma Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElranatamabDrug
BCMA-CD3 bispecific antibody
Standard of CareDrug
Standard of Care
| Study group | Role | What they receive |
|---|---|---|
| Elranatamab | Patients treated with elranatamab from the MagnetisMM-5 trial Receives: Drug: Elranatamab | |
| Standard of care | Patients treated with standard-of-care therapies from real-world data source Receives: Drug: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Real World Progression Free Survival (rwPFS)
Measured: From the index date through the end of the study period, approximately 6 months.
Overall Survival (OS)
Measured: From the index date through the end of the study period, approximately 6 months.
Time to next treatment (TTNT)
Measured: From the index date through the end of the study period, approximately 6 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2026
- Study start9 Nov 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07927023
- Sponsor's protocol ID
- C1071056
- Status last verified
- Nov 2026
- First submitted
- 3 Nov 2026
- Last updated
- 9 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effectiveness of Elranatamab Monotherapy in the MagnetisMM-5 Clinical Trial Versus a Real-World External Control Arm of Patients With Relapsed/Refractory Multiple Myeloma With Prior Treatment of Lenalidomide and Proteasome Inhibitor From the Therapy Monitor Multiple Myeloma Dataset in Germany (BasecaMMp)
- ClinicalTrials.gov ID
- NCT07927023
- Acronym / sponsor ID
- C1071056
- Conditions
- Multiple Myeloma
- Keywords
- Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 9 Nov 2026 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 9 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, we will use data from the phase 3 clinical trial (MagnetisMM-5). We will also use data from a real-world database, representing the SOC in clinical practice. This study does not seek any participants for enrollment. We will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help us to know how well elranatamab can be used for RRMM treatment.
Detailed description
Comparative effectiveness of elranatamab monotherapy in the MagnetisMM-5 clinical trial versus a real-world external control arm of patients with relapsed/refractory multiple myeloma with prior treatment of lenalidomide and proteasome inhibitor from the Therapy Monitor Multiple Myeloma dataset in Germany (BasecaMMp)
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Elranatamab | – | Drug: ElranatamabPatients treated with elranatamab from the MagnetisMM-5 trial |
| Standard of care | – | Drug: Standard of CarePatients treated with standard-of-care therapies from real-world data source |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated with elranatamab will come from the MagnetisMM-5 trial. Patients treated with the standard-of-care therapies will come from electronic health record databases in Germany.
Key inclusion criteria (5 listed)
- Male or Female aged 18 years and older at index date
- Diagnosis of MM
- Measurable disease according to IMWG criteria
- Prior anti-MM therapy (1-3 prior lines of therapy)
- ECOG performance status ≤2
Key exclusion criteria (14 listed)
- Acute plasma cell leukemia
- Amyloidosis
- Smoldering MM
- Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
- Ongoing Grade 2 or higher peripheral sensory or motor neuropathy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ElranatamabBCMA-CD3 bispecific antibody | Drug | Elranatamab |
| Standard of CareStandard of Care | Drug | Standard of care |
Primary outcome
Real World Progression Free Survival (rwPFS)
Time frame: From the index date through the end of the study period, approximately 6 months.
Overall Survival (OS)
Time frame: From the index date through the end of the study period, approximately 6 months.
Time to next treatment (TTNT)
Time frame: From the index date through the end of the study period, approximately 6 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2026.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Multiple Myeloma
Active, not recruitingPhase 2
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingObservational study
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Multiple Myeloma, Lymphoma, Non-Hodgkin
Enrolling by invitationObservational study
Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
Multiple Myeloma
Active, not recruitingObservational study
Agriculture Health Study
Prostate Cancer, Pesticide Exposures
Recruiting
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pfizer CT.gov Call Center study director
Pfizer
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Myeloma, run by Pfizer.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Real World Progression Free Survival (rwPFS) (time frame: From the index date through the end of the study period, approximately 6 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2026.